| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-062 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于子公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"或"蓝帆医疗"）于2023年9月28日 召开第六届董事会第三次会议，审议并通过了《关于2023年度新增银行授信及担保的 议案》，为满足生产经营对资金的需求，公司全资子公司山东蓝帆新材料有限公司 （以下简称"山东新材料"）拟向兴业银行股份有限公司（以下简称"兴业银行"）申 请授信额度不超过10,000万元人民币，公司拟为该笔授信提供保证担保，担保金额不 超过10,000万元人民币，担保期限一年。 上述内容详见公司于2023年9月29日刊登在《中国证券报》、《上海证券报》、 《证券时报》、《证券日报》和巨潮资讯网（www. cninfo.com.cn）上的《关于2023 年度新增银行授信及担保的公告》（公告编号： ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-061 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于2023年第三季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 根据《深圳证券交易所股票上市规则》、《深圳证券交易所可转换公司债券交易 实施细则》的有关规定，蓝帆医疗股份有限公司（以下简称"公司"）现将 2023 年第三季 度可转换公司债券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5月 28 日公开发行了3,144.04万张可转债，每张面值 100元，发行总额314,404 万元。 证券代码：002382，证券简称：蓝帆医疗 债券代码：128108，债券简称：蓝帆转债 转股价格：人民币 17.84 元/股 转股时间：2020 年 12 月 3 日至 2026 年 5 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-058 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于暂不向下修正"蓝帆转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2023 年 9 月 28 日，蓝帆医疗股份有限公司（以下简称"公司"）股价已 出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情形， 已触发"蓝帆转债"转股价格向下修正条件。 2、经公司第六届董事会第三次会议审议通过，公司董事会决定本次不向下修正 "蓝帆转债"转股价格，且自本次董事会审议通过之日起的六个月内（2023 年 9 月 28 日至 2024 年 3 月 27 日），如再次触发"蓝帆转债"转股价格向下修正条件，亦不提 出向下修正方案。自 2024 年 3 月 28 日之后，若再次触发"蓝帆转债"转股价格的向 下修正条件，届时公司董事会将再次召开会议决定是否行使"蓝帆转债"转股价格的 向下修正权利。 根据《蓝 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-057 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三次会议于 2023 年 9 月 22 日以电子邮件的方式发出通知，于 2023 年 9 月 28 日以通讯表决的方式召开。 本次会议应参加会议董事 7 人，实际参加会议董事 7 人；全体董事以通讯的方式出席 会议。公司董事长刘文静女士主持了本次会议。会议的通知、召开、表决程序符合《中 华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于不向下修正"蓝帆转债"转股价格的议案》； 截至2023年9月28日，公司股票已出现连续三十个交易日中至少有十五个交易日的 收盘价低于当期转股价格85%的情形，已触发"蓝帆转债"转股价格向下修正条件。 具体内容详见 ...

经核查，我们认为公司的子公司本次新增向银行申请授信将主要用于子公司日常 运营和业务发展，有利于保障子公司发展必要的资金需求。本次新增担保的风险在可 控范围内，担保事项的审议程序符合《深圳证券交易所股票上市规则》等法律法规以及 《公司章程》的有关规定，不存在损害公司和股东利益，特别是中小股东权益的行为。 我们同意子公司本次新增银行授信及担保事项。 （以下无正文） （此页无正文，为蓝帆医疗股份有限公司独立董事关于第六届董事会第三次会议相 关事项的独立意见签署页） 蓝帆医疗股份有限公司 独立董事关于第六届董事会第三次会议相关事项 的独立意见 作为蓝帆医疗股份有限公司（以下简称"公司"）的独立董事，根据《中华人民共 和国公司法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等相关规定及《蓝帆医疗股份有限公司章程》（以下简称"《公司章程》"）的要求， 我们就公司第六届董事会第三次会议相关事项发表独立意见如下： 关于 2023 年度新增银行授信及担保的独立意见 刘胜军 董书魁 乔贵涛 二〇二三年九月二十八日 独立董事签名： ...

蓝帆医疗股份有限公司 关于2023年度新增银行授信及担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-059 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司（以下简称"公司"或"蓝帆医疗"）于2023年9月28日召 开了第六届董事会第三次会议，以同意票7票、反对票0票、弃权票0票的表决结果审议 并通过了《关于2023年度新增银行授信及担保的议案》，具体情况如下： 一、担保情况概述 1、为保证公司子公司Biosensors International Group, Ltd.（以下简称"柏盛国际"） 生产经营及信贷融资计划的实施，柏盛国际拟向China CITIC Bank International Limited 申请授信额度9,000万欧元，公司及子公司CB Cardio Holdings II Limited（以下简称 "CBCH II"）、CB Cardio Holdings I Limite ...

| .证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-060 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于控股股东部分股份解除质押及质押、展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）于近日接到控股股东 淄博蓝帆投资有限公司（以下简称"蓝帆投资"）的通知，获悉蓝帆投资将其持有的本 公司部分股份办理了解除质押及质押、展期手续，具体情况如下： 上述股份的原质押情况，详见公司分别于 2021 年 10 月 8 日、2022 年 2 月 9 日、 2022 年 4 月 21 日、2022 年 4 月 23 日、2022 年 4 月 27 日、2022 年 5 月 18 日、2022 年 9 月 29 日披露在指定信息媒体的《关于公司控股股东进行股票质押式回购交易的公 告》（公告编号：2021-088）、《关于公司控股股东部分股份质押的公告》（公告编号：2022- 009）、《关于公司控股股东部分 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-056 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 17.84 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 5、截至 2023 年 9 月 21 日，蓝帆医疗股份有限公司（以下简称"公司"）股票已 有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发"蓝帆转债"转股价格向 下修正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股 价格，并及时履行信息披露义务。 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 2 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥2,261,941,112.09, a decrease of 12.12% compared to ¥2,574,007,108.85 in the same period last year[20]. - The net loss attributable to shareholders was ¥236,609,876.96, representing a 31.13% increase in loss compared to ¥180,432,657.11 in the previous year[20]. - The net cash flow from operating activities was negative at ¥109,962,361.59, a decline of 148.79% from a positive cash flow of ¥225,358,387.82 in the same period last year[20]. - The basic earnings per share were -¥0.23, a decrease of 27.78% from -¥0.18 in the previous year[20]. - Total assets at the end of the reporting period were ¥15,471,760,236.09, down 2.52% from ¥15,872,538,527.91 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 4.76% to ¥10,049,531,760.69 from ¥10,551,930,175.12 at the end of the previous year[20]. - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company reported a significant increase in non-operating income from government subsidies amounting to ¥22,412,114.79[24]. - The company experienced a 50.17% increase in the net loss after deducting non-recurring gains and losses, totaling ¥316,201,251.25[20]. - The weighted average return on net assets was -2.28%, a decline from -1.71% in the previous year[20]. Market Position and Growth - The company has developed into a multinational medical device comprehensive platform enterprise, focusing on "A+X" development strategy across various medical device segments[28]. - The cardiovascular business is a key area, with the Chinese medical device market growing from RMB 843.8 billion in 2021 to RMB 958.2 billion in 2022, reflecting a compound annual growth rate (CAGR) of approximately 17.5% over seven years[29][30]. - The company holds a leading position in the disposable glove market, with a PVC glove export market share exceeding 23% and a nitrile glove export market share exceeding 20%[36]. - The global emergency care application market is projected to grow from RMB 102.89 billion in 2021 to RMB 592.98 billion by 2027, with a CAGR of nearly 34%[37]. - The company’s production capacity for various types of gloves is approximately 50 billion pieces per year, placing it among the industry leaders[36]. - The company’s cardiovascular division is recognized as the fourth largest in the world for the research, production, and sales of cardiac stents[33]. - The health protection business is experiencing rapid growth, with the disposable glove segment expected to maintain an annual growth rate of over 12% in the coming years[34]. - The company is advancing towards global expansion, focusing on technology, brand, and standard exports to meet international market demands[28]. - The emergency rescue product market is expanding, with increasing societal awareness and government emphasis on emergency preparedness[36]. Product Development and Innovation - The company aims to enhance its competitive edge by establishing a robust supply chain and improving production efficiency to adapt to global market demands[35]. - In the first half of 2023, the company sold over 20,000 units of the BioFreedom® drug-coated coronary stent in China, a significant increase compared to the same period last year[41]. - The company has established long-term strategic partnerships with major automotive manufacturers such as Tesla, Mercedes-Benz, and BMW for the supply of automotive first aid kits, capitalizing on the growing demand due to increased exports of new energy vehicles[38]. - The health protection business saw a year-on-year increase of 8.6% in PVC glove exports, capturing over 23% of the market share, while nitrile glove exports increased by 1.5%, achieving over 20% market share[44]. - The company has developed and launched several new products, including the BA9™ DCB balloon catheter and the EXPANSAL® biodegradable drug-eluting stent, enhancing its product portfolio in the cardiovascular sector[42]. - The production capacity for cardiovascular devices exceeds 1.87 million units per year, with the company ranking second in domestic coronary stent implant volume[39]. - The company holds nearly 460 global patents in its cardiovascular division, including over 380 invention patents, demonstrating its strong focus on innovation[43]. - The company’s production line for nitrile gloves has achieved an operating rate exceeding 90%, positioning it as a leader in the industry[44]. - The introduction of automated production processes has improved efficiency, with energy savings exceeding 20% through the use of metal hand molds in the PVC glove production process[46]. - The company has expanded its product offerings beyond medical protection to include kitchen and household cleaning gloves, diversifying its market reach[44]. Sales and Marketing Strategies - The new marketing strategy initiated in late 2021 has resulted in the addition of over 500 new clients across various channels, enhancing the company's market reach[50]. - The company's Douyin flagship store gained 10,000 followers within two months, with daily sales exceeding 10,000 yuan for nitrile household gloves[51]. - The launch of the "Invisible Mask" and "Nano Antibody Spray" on e-commerce platforms has positioned these products as top sellers in their categories within a month[51]. - The company is actively expanding its product offerings in the cardiovascular sector, with several key products registered and available for sale as of June 30, 2023[52]. - The company is focused on providing comprehensive emergency rescue solutions, leveraging global technology to enhance domestic market offerings[49]. - The company is pursuing opportunities in the export market for first aid kits tailored for new energy vehicles, aligning with the growing trend in the automotive industry[48]. - The health protection products segment includes disposable gloves, with categories such as nitrile gloves, PVC gloves, latex gloves, and TPE/CPE gloves, widely used in medical, food processing, industrial safety, and daily protection[53]. Environmental and Social Responsibility - The company has obtained pollution discharge permits for its subsidiaries, with validity periods extending until December 30, 2026, for several entities[147]. - The emissions data indicates that the company’s subsidiary, Zibo Blue Sail New Materials, reported a total waste gas discharge of 17.95 tons per annum, well below the permitted limit of 50 mg/m³[148]. - The company’s subsidiaries have implemented advanced pollution control measures, including ultra-low emission transformations for boiler systems and the installation of RTO VOCs treatment equipment[149]. - The wastewater treatment facilities at Zibo Blue Sail Health Technology and Zibo Blue Sail Protective Products are operational and meet environmental standards, with regular monitoring in place[149]. - The company has conducted 18 emergency response drills for environmental incidents, enhancing its capability to manage pollution events[150]. - Environmental protection investments and taxes have been duly paid by all subsidiaries in compliance with legal requirements[150]. - The company has established a self-monitoring scheme for emissions, with real-time data uploaded to local environmental authorities[151]. - No administrative penalties were incurred during the reporting period due to environmental issues[151]. - The company emphasizes energy conservation and low-carbon development as part of its environmental strategy[150]. - The subsidiaries are connected to the Shandong Provincial Environmental Monitoring Center for real-time data sharing[149]. Legal and Compliance Matters - The company is currently involved in multiple legal disputes, with claims totaling approximately 228.67 million pending in court[180]. - The company has reported a total of 118 million yuan in labor dispute arbitration claims[178]. - The company is actively involved in multiple legal proceedings, including appeals and enforcement actions[178]. - The company has not disclosed any significant new product developments or market expansions in the current reporting period[177]. - The company continues to monitor and manage its legal risks associated with ongoing litigation[178]. - The company has committed to avoiding competition and related party transactions, ensuring strict compliance since April 21, 2016[168]. - The company reported a commitment to maintain independence in personnel, assets, finance, and operations, effective from April 21, 2016, and is strictly adhering to this commitment[168]. - The company guarantees the independence of its financial department and accounting system, ensuring no shared bank accounts with shareholders, effective from December 22, 2017[169]. - The company has pledged to maintain business independence and avoid substantial competition or unfair related transactions, effective from December 22, 2017[169]. - The company has not directly or indirectly invested in any competing businesses as of the date of the commitment letter, ensuring no conflict with its main operations[169]. Future Outlook - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 25% year-on-year, aiming for a total revenue of 1.875 billion RMB[171]. - New product launches are expected to contribute an additional 300 million RMB in revenue by the end of 2023, focusing on innovative medical devices[171]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next fiscal year through strategic partnerships and marketing initiatives[171]. - The company has set a performance guidance for the next half of the year, aiming for a revenue increase of at least 10%[183]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product portfolio[183].

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2023-051 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次解除 质押股份 数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 起始日 解除 日期 质权人 蓝帆 投资 是 23,000,000 9.80 2.28 2020 年 8 月 31 日 2023 年 8 月 9 日 兴业银行 股份有限 公司淄博 6,000,000 2.56 0.60 分行 2021 年 6 月 24 日 2023 年 8 月 9 日 合计 29,000,000 12.35 2.88 - - - 一、股东股份解除质押的基本情况 | 股 东 | 是否为 控股股 东或第 | 本次质押 | 占其 所持 | 占公 司总 | 是否 | 是否 为补 | 质押起 | | 质押 ...